Christopher Freeburn

Christopher Freeburn

InvestorPlace Writer

Christopher T. Freeburn has been a financial writer and editor for more than 10 years. He has worked at industry trade publications like Food Logistics, ChemicalWeek and Institutional Investor. His freelance articles have appeared in a variety of magazines, including Technology Review, Audubon and USA Weekend. He lives in Westchester County, just outside New York City.”

Recent Articles

Biotechs Beat Q3 Earnings, Revenue Estimates

By Christopher Freeburn, InvestorPlace Writer

Amgen, Gilead Science and Questcor Pharmaceuticals posted third-quarter earnings and revenue that beat Wall Street forecasts.

Bristol-Myers, Eli Lilly Miss Q3 Forecasts, Shares Slide

By Christopher Freeburn, InvestorPlace Writer

Bristol-Myers Squibb and Eli Lilly reported third-quarter earnings that missed Wall Street estimates as generic competition slammed drug sales.

Defense Stocks Move Higher on Mixed Earnings

By Christopher Freeburn, InvestorPlace Writer

Defense stocks rose as Boeing and Northrop Grumman raised their annual outlooks and Lockheed Martin topped estimates, but General Dynamics missed forecasts.

AT&T Falls Short on Q3 Revenue, Subscribers

By Christopher Freeburn, InvestorPlace Writer

AT&T posted third-quarter revenue and subscriber growth that disappointed Wall Street, but topped earnings estimates.

Gold Futures Hit Six-Week Low as Dollar Rises

By Christopher Freeburn, InvestorPlace Writer

Lackluster corporate earnings reports cast a pall, raising worries about the global economy and sending gold down in Tuesday trading.

Load More